MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1186/1758-2652-15-1

Медицинская библиотека · Journal of the International AIDS Society · 2012

Failure to prescribe pneumocystis prophylaxis is associated with increased mortality, even in the cART era: results from the Treat Asia HIV observational database.

Lim Poh-Lian, Zhou Jialun, Ditangco Rossana A, Law Matthew G, Sirisanthana Thira, Kumarasamy Nagalingeswaran, Chen Yi-Ming A, Phanuphak Praphan, Lee Christopher K C, Saphonn Vonthanak, Oka Shinichi, Zhang Fujie, Choi Jun Y, Pujari Sanjay, Kamarulzaman Adeeba, Li Patrick C K, Merati Tuti P, Yunihastuti Evy, Messerschmidt Liesl, Sungkanuparph Somnuek, TREAT Asia HIV Observational Database

СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

Pneumocystis jiroveci pneumonia (PCP) prophylaxis is recommended for patients with CD4 counts of less than 200 cells/mm3. This study examines the proportion of patients in the TREAT Asia HIV Observational Database (TAHOD) receiving PCP prophylaxis, and its effect on PCP and mortality.

METHODS

TAHOD patients with prospective follow up had data extracted for prophylaxis using co-trimoxazole, dapsone or pentamidine. The proportion of patients on prophylaxis was calculated for each calendar year since 2003 among patients with CD4 counts of less than 200 cells/mm3. The effect of prophylaxis on PCP and survival were assessed using random-effect Poisson regression models.

RESULTS

There were a total of 4050 patients on prospective follow up, and 90% of them were receiving combination antiretroviral therapy. Of those with CD4 counts of less than 200 cells/mm3, 58% to 72% in any given year received PCP prophylaxis, predominantly co-trimoxazole. During follow up, 62 patients developed PCP (0.5 per 100 person-years) and 169 died from all causes (1.36/100 person-years). After stratifying by site and adjusting for age, CD4 count, CDC stage and antiretroviral treatment, those without prophylaxis had no higher risk of PCP, but had a significantly higher risk of death (incident rate ratio 10.8, p<0.001). PCP prophylaxis had greatest absolute benefit in patients with CD4 counts of less than 50 cells/mm3, lowering mortality rates from 33.5 to 6.3 per 100 person-years.

CONCLUSIONS

Approximately two-thirds of TAHOD patients with CD4 counts of less than 200 cells/mm3 received PCP prophylaxis. Patients without prophylaxis had significantly higher mortality, even in the era of combination ART. Although PCP may be under-diagnosed, these data suggest that prophylaxis is associated with important survival benefits.

Для цитирования: Lim Poh-Lian, Zhou Jialun, Ditangco Rossana A, Law Matthew G, Sirisanthana Thira, Kumarasamy Nagalingeswaran, Chen Yi-Ming A, Phanuphak Praphan, Lee Christopher K C, Saphonn Vonthanak, Oka Shinichi, Zhang Fujie, Choi Jun Y, Pujari Sanjay, Kamarulzaman Adeeba, Li Patrick C K, Merati Tuti P, Yunihastuti Evy, Messerschmidt Liesl, Sungkanuparph Somnuek, TREAT Asia HIV Observational Database. Failure to prescribe pneumocystis prophylaxis is associated with increased mortality, even in the cART era: results from the Treat Asia HIV observational database.. Journal of the International AIDS Society. 2012. DOI: 10.1186/1758-2652-15-1.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.